Novartis AG: Form 20-F/A for the period ended Dec 31, 2022
Filed with the SEC on May 15, 2023 and accepted by EDGAR at May 15, 2023, 16:40 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $15.49bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2022-01-01 to 2022-12-31 | $36.34bn | ifrs-full:GrossProfit |
| Operating income | 12 months2022-01-01 to 2022-12-31 | $9.20bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $1.42bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2022-01-01 to 2022-12-31 | $6.96bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | $3.17 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | $3.19 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | $14.24bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $1.20bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2022-12-31 | $7.52bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2022-12-31 | $36.91bn | ifrs-full:CurrentAssets |
| Total assets | At period end2022-12-31 | $117.45bn | ifrs-full:Assets |
| Current liabilities | At period end2022-12-31 | $28.66bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2022-12-31 | $58.03bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $59.34bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2022-12-31 | 2,119,609,057 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001370368-23-000048. Last ingested by Listed: Nov 13, 2026, 16:23 ET. Listed shows no prices and gives no investment advice.